Maxcyte annual operating expenses
2019
2020
2021
2022
2023
2024
2025
Maxcyte Operating Expenses Growth & History (MXCT)
Maxcyte's operating expenses was $78.7M for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $78.7M | −$4.0M | −4.86% |
| 2024 | 2024-12-31 | $82.7M | −$2.1M | −2.50% |
| 2023 | 2023-12-31 | $84.8M | $18.3M | +27.54% |
| 2022 | 2022-12-31 | $66.5M | $18.1M | +37.35% |
| 2021 | 2021-12-31 | $48.4M | $14.0M | +40.56% |
| 2020 | 2020-12-31 | $34.5M | $2.9M | +9.25% |
| 2019 | 2019-12-31 | $31.5M | — | — |
Maxcyte quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15.8M | −$5.4M | −25.39% |
| Q1 2026 | 2026-03-31 | $14.3M | −$6.9M | −32.66% |
| Q4 2025 | 2025-12-31 | $16.9M | −$2.4M | −12.41% |
| Q3 2025 | 2025-09-30 | $19.4M | −$907,000 | −4.47% |
| Q2 2025 | 2025-06-30 | $21.2M | $306,000 | +1.46% |
| Q1 2025 | 2025-03-31 | $21.2M | −$1.0M | −4.62% |
| Q4 2024 | 2024-12-31 | $19.3M | −$2.9M | −12.96% |
| Q3 2024 | 2024-09-30 | $20.3M | −$874,000 | −4.13% |
| Q2 2024 | 2024-06-30 | $20.9M | $169,000 | +0.81% |
| Q1 2024 | 2024-03-31 | $22.2M | $1.5M | +7.03% |
| Q4 2023 | 2023-12-31 | $22.2M | $4.6M | +25.87% |
| Q3 2023 | 2023-09-30 | $21.2M | $4.2M | +24.59% |
| Q2 2023 | 2023-06-30 | $20.7M | $3.5M | +20.40% |
| Q1 2023 | 2023-03-31 | $20.8M | $6.1M | +41.34% |
| Q4 2022 | 2022-12-31 | $17.6M | $3.7M | +26.99% |
| Q3 2022 | 2022-09-30 | $17.0M | $5.3M | +45.95% |
| Q2 2022 | 2022-06-30 | $17.2M | $6.5M | +60.38% |
| Q1 2022 | 2022-03-31 | $14.7M | $2.5M | +20.61% |
| Q4 2021 | 2021-12-31 | $13.9M | — | — |
| Q3 2021 | 2021-09-30 | $11.6M | $2.8M | +31.21% |
| Q2 2021 | 2021-06-30 | $10.7M | $3.2M | +42.66% |
| Q1 2021 | 2021-03-31 | $12.2M | — | — |
| Q3 2020 | 2020-09-30 | $8.9M | — | — |
| Q2 2020 | 2020-06-30 | $7.5M | — | — |
Maxcyte operating expenses trends
Over the last five fiscal years, Maxcyte's operating expenses increased from $34.5M to $78.7M, a change of $44.2M. The latest reported quarter, Q2 2026, shows $15.8M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte source filings ↗